ProImmune
ProImmune is a UK-based life sciences company that develops MHC-based immunological reagents (pentamers, tetramers, monomers) and proprietary Ankyron binding proteins, alongside contract research services for immunogenicity and T cell epitope analysis, serving pharma, biotech, academic, and government customers worldwide.
- Company typePrivate
- Founded2001
- HeadquartersOxford, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ProImmune does
ProImmune Ltd is a privately held UK life-sciences company headquartered in Oxford that develops and commercializes immunological reagents and contract research services used to study and manage adaptive immune responses. Its core reagent platform is built on Major Histocompatibility Complex (MHC) technology, including Pro5 MHC Class I Pentamers, ProT2 MHC Class II Tetramers, ProM1/ProM2 monomers, and CD1d/MR1 tetramers that enable detection of antigen-specific T cells in flow cytometry. The company has built a differentiated second platform, Ankyrons — engineered ankyrin-repeat scaffold proteins (~15 kDa) selected in vitro from trillion-clone ribosome-display libraries without animal immunization — that are positioned as reproducible, affinity-mature alternatives to conventional antibodies across 60+ pathogen and disease targets.
ProImmune monetizes through three revenue streams: catalog and custom reagent sales (pentamers, tetramers, monomers, Ankyrons, peptides via its thinkpeptides brand) distributed through a direct sales force, e-commerce storefront, and distributor network; fee-for-service contract research assays including ProPresent antigen presentation, ProMap/ProScern proliferation assays, REVEAL/ProVE MHC-peptide binding for epitope discovery, ProStorm cytokine release, ProSpot ELISpot, immunogenicity risk assessment, and HLA typing; and custom synthesis/development work (custom Ankyrons, custom multimers, peptide libraries). Pricing is quote-based and not publicly disclosed.
The customer base spans large pharmaceutical companies (Pfizer, Novartis, GSK, Roche, Bristol-Myers Squibb, Bayer, Dr. Reddy's), biotechnology firms (Adaptimmune, Immunovaccine), academic medical centers (University of Oxford, Harvard Medical School, Duke-NUS, Karolinska, Fred Hutchinson), and government agencies (USAMRIID, FDA, DSTL). Applications span vaccine and biotherapeutic immunogenicity, infectious disease (including BSL-4 pathogens), cancer immunotherapy, autoimmunity, transplantation, and emerging veterinary/animal health work. The company sells globally through regional sales contacts in the US/Canada, Asia-Pacific, and the UK/EU, with named distributor relationships in international markets.
ProImmune firmographics
Firmographics- Name
- ProImmune
- Legal name
- ProImmune Ltd
- Website
- https://proimmune.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ProImmune is a UK-based life sciences company that develops MHC-based immunological reagents (pentamers, tetramers, monomers) and proprietary Ankyron binding proteins, alongside contract research services for immunogenicity and T cell epitope analysis, serving pharma, biotech, academic, and government customers worldwide.
- Ownership category
- akta.pro rank
ProImmune industry classification
Industry- Product category
- Immunology Reagents and Contract Research Services
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)
- akta.pro secondary industries
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
Keywords
Where ProImmune is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
ProImmune business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Immunological Reagent Products: Sale of proprietary immunological reagents including Ankyrons, MHC Pentamers, Tetramers, Monomers, CD1d/MR1 Tetramers, and peptide products. Products sold through catalog, custom synthesis, and e-commerce platform.
- Contract Research Services: Fee-for-service laboratory assays including immunogenicity testing, T cell proliferation assays, cytokine release assays, ELISpot assays, HLA typing, and custom assay development. Services support preclinical and clinical drug development.
- Custom Synthesis & Development: Custom peptide synthesis, custom Ankyron development, and custom multimer production based on specific customer research requirements.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
ProImmune product offering
Product offeringCore offering
ProImmune develops, manufactures, and sells proprietary immunological reagents — including Ankyron® target binding proteins, MHC Class I Pentamers (Pro5®), MHC Class II Tetramers (ProT2®), MHC monomers (ProM1/ProM2, ProVE® SL), CD1d and MR1 Tetramers, and custom peptides (thinkpeptides®) — for immunology research. The company also provides fee-for-service contract research assays such as ProPresent® antigen presentation assays, ProMap®/ProScern® T cell proliferation assays, REVEAL®/ProVE® MHC-peptide binding assays, ProStorm® cytokine release assays, ProSpot® ELISpot assays, and typeHLA HLA typing to support biotherapeutic immunogenicity risk assessment, vaccine development, and T cell research.
Product overview
ProImmune offers an integrated platform of immunological reagents and contract research services for T cell research, spanning MHC multimers (pentamers, tetramers, monomers), novel Ankyron binding reagents, custom peptide synthesis, and comprehensive assay services. The product portfolio centers on Pro5 MHC Class I Pentamers and ProT2/ProM2 MHC Class II reagents for detecting antigen-specific T cells, complemented by the innovative Ankyron target binding platform (engineered ankyrin-repeat proteins for any target). The services division includes ProPresent antigen presentation assays, ProMap/ProScern T cell proliferation assays, REVEAL epitope discovery, ProStorm cytokine release assays, and full immunogenicity assessment services for biotherapeutic development. The thinkpeptides custom synthesis brand provides peptides for epitope mapping and immune monitoring. Research applications span infectious diseases, oncology, autoimmunity, allergy, transplant immunology, and vaccine development.
Differentiator
Problem solved
Functional benefit
Brands
- Ankyrons®: Next-generation target binding reagents based on engineered ankyrin-repeat scaffold for detection and binding applications
- Pro5® MHC Class I Pentamers
- ProVE®
- ProT2® MHC Class II Tetramers
- ProM1™ MHC Class I Monomers
- ProM2® MHC Class II Monomers
- thinkpeptides®
- ProMix™ Peptide Pools
- REVEAL®
- ProPresent®
- ProMap®
- ProScern®
- ProStorm®
- ProSpot®
- typeHLA
- CD1d Tetramers
- MR1 Tetramers
Products and services
- Ankyrons® Next-generation target binding reagents (~15 kDa) based on engineered ankyrin-repeat scaffold proteins, generated through fully in vitro high-throughput selection from a trillion-clone ribosome display library without animal immunization; available for 60+ pathogens and rapidly developable for emerging disease targets. Used by immunology and infectious disease researchers as cost-effective, reproducible alternatives to custom antibodies.
- Pro5® MHC Class I Pentamers
Quantifiable outcome
- Ankyrons available for 60+ pathogens and disease vectors
- +2 more outcomes
Companies that use ProImmune
Customer profileNamed customers17 records
Segments4 records
Ideal customer profiles3 records
ProImmune technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
ProImmune partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- University of Texas Medical Branch (UTMB) Galveston National LaboratorycoreCollaboration to develop innovative tools for studying high-consequence emerging and endemic infectious diseases. ProImmune's Ankyrons will be evaluated as molecular tools to enable precise detection, localization, and functional interrogation of viral proteins in high-containment research environments (BSL-4). Initial focus on Bundibugyo virus, Zaire ebolavirus, Sudan ebolavirus, Reston ebolavirus, Human Enterovirus 71, and Mpox virus.
- Roslin Institute (University of Edinburgh)coreCollaboration to develop and validate species-specific Ankyron binders for veterinary immunology research across porcine, bovine, avian, and salmonid species. Validated binder data will be made available through the Immunological Toolbox website, a BBSRC-funded initiative supporting the veterinary immunology research community.
- The Pirbright InstitutecoreStrategic partnership to develop target-binding Ankyron reagents for animal health research applications. ProImmune has generated and provided new Ankyrons to Pirbright for validation, including targets for bovine, porcine, avian, and mosquito proteins, as well as Foot and Mouth Disease and African Swine Fever - areas underserved by traditional antibody technology.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
ProImmune competitors and assessment
Company assessmentDirect peers
- MBL International: Japanese life science reagent company and the historical leader in MHC tetramers and multimer-based T cell detection. Directly competes with ProImmune's Pro5 Pentamers, ProT2 Tetramers, and CD1d/MR1 tetramers for the same immunology research customer base.
- Immudex: Denmark-based developer of MHC Dextramers and immune monitoring reagents used for antigen-specific T cell detection in research and clinical settings. Closely comparable in product format (multimers), application (flow cytometry), and target customer (immunology labs and cell therapy developers).
- JPT Peptide Technologies (Bio-Techne): Custom peptide synthesis and PepSpot/Peptide Microarray specialist serving immunology, vaccine, and immunogenicity customers. Directly comparable to ProImmune's thinkpeptides and PEPscreen custom peptide business and adjacent to its REVEAL epitope discovery service.
- GenScript: Global life science services and reagent provider offering custom peptide synthesis, antibody production, gene synthesis, and immunology-related services. Competes with ProImmune on custom synthesis, antibody alternatives, and immunogenicity-related CRO work.
Broad incumbents
- BioLegend (Revvity): Large catalog immunology reagent vendor offering flow cytometry antibodies, multimers, and immunoassay kits across research and translational markets. Competes on catalog breadth and bundled reagent panels rather than MHC specialization.
- Abcam (Danaher): One of the largest research antibody and reagent catalogs globally, including antibodies relevant to immunology, flow cytometry, and T cell biology. Competes with ProImmune's antibody offering and adjacent reagent categories, but at far greater catalog scale.
- Cell Signaling Technology: Major US research antibody and immunoassay reagent company with a deep catalog across immunology, immuno-oncology, and cell signaling. Competes indirectly with ProImmune in T cell and immunology reagent purchasing decisions, particularly in academic accounts.
- Beckman Coulter Life Sciences: Flow cytometry instruments and reagents vendor serving immunology and cell therapy labs worldwide. Competes for reagent dollars attached to flow cytometry workflows in which ProImmune's pentamers and tetramers are used.
- Eurofins Scientific: Global CRO with deep immunogenicity, bioassay, and vaccine testing capabilities. Competes with ProImmune's contract research services (ProPresent, ProMap, ProStorm, REVEAL) for outsourced immunogenicity and immunology assay work, particularly from large pharma.
Emerging players
- Navigo Proteins: German biotech developing alternative scaffold binding proteins (e.g., affilin scaffolds) for research and therapeutic applications. The closest direct technology analog to ProImmune's Ankyron platform, though focused on different scaffolds and primarily therapeutic use cases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ProImmune social profiles
Digital presenceProImmune financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProImmune leadership team
Management profileNumber of profiles
Profiles2 records
ProImmune funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProImmune M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProImmune
What does ProImmune do?
ProImmune develops, manufactures, and sells proprietary immunological reagents — including Ankyron® target binding proteins, MHC Class I Pentamers (Pro5®), MHC Class II Tetramers (ProT2®), MHC monomers (ProM1/ProM2, ProVE® SL), CD1d and MR1 Tetramers, and custom peptides (thinkpeptides®) — for immunology research. The company also provides fee-for-service contract research assays such as ProPresent® antigen presentation assays, ProMap®/ProScern® T cell proliferation assays, REVEAL®/ProVE® MHC-peptide binding assays, ProStorm® cytokine release assays, ProSpot® ELISpot assays, and typeHLA HLA typing to support biotherapeutic immunogenicity risk assessment, vaccine development, and T cell research.
Is ProImmune a public or private company?
ProImmune is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ProImmune founded?
ProImmune was founded in 2001. It employs 11 to 50 people.
Where is ProImmune based?
ProImmune is headquartered in Oxford, United Kingdom, in the Europe region.
How does ProImmune make money?
Three revenue lines are on record. Immunological Reagent Products are the primary driver. The others are contract Research Services and custom Synthesis & Development.
Who are ProImmune's main competitors?
Direct peers on record are MBL International, Immudex, JPT Peptide Technologies (Bio-Techne) and GenScript. Broad incumbents are BioLegend (Revvity), Abcam (Danaher), Cell Signaling Technology, Beckman Coulter Life Sciences and Eurofins Scientific. Navigo Proteins is listed as an emerging player.
Does ProImmune have an API?
No public API is recorded for ProImmune.
What industry is ProImmune in?
ProImmune's product category is Immunology Reagents and Contract Research Services. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.